Advertisement

Electron Spin Resonance Studies of 1:1:1 Bleomycin-Cobalt(II)-Qxygen Adduct Complex

  • Yukio Sugiura

Abstract

Bleomycin has been used extensively in the chemotherapy and radiodiagnosis of cancer (1). One of the most important aspects of its chemistry is its ability to coordinate a variety of metals. Recently, bleomycin-metal complexes have attracted particular attention because of their interesting behavior: (i) the copper(II) complex is a metabolic form of bleomycin (2), (ii) γ-emitting metal complexes such as 57CO, 99mTc, and 111In have been investigated as a means of visualizing tumors(3), and (iii) an oxygen-labile iron(II) complex may play an important role in DNA degradation by bleomycin(4,5). Sausville et al. reported that the conversion of SV40 DNA to acid-soluble products occurs at approximately equimolar levels of Fe(II), bleomycin, and DNA(4). Takita et al. have proposed that an oxygen activated by the bleomycin-Fe(II) complex is involved in the action of bleomycin on DNA(5). Additionally, it has been suggested that superoxide radical is one of the chemical mediators responsible for the enhancement of DNA chain breakage by bleomycin (6). Herein, the 1:1 bleomycin A2-Co(II) complex and its oxygen adduct complexes have been characterized by electron spin resonance (ESR) spectroscopy; the present results should serve to facilitate an understanding of the degradation of DNA by the bleomycinFe(II)-02 complex.

Keywords

Electron Spin Resonance Electron Spin Resonance Spectrum Electron Spin Resonance Study Electron Spin Resonance Result Metabolic Form 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Umezawa, Fed. Proc., 33, 2296 (1974).PubMedGoogle Scholar
  2. 2.
    M. Kanao, S. Tomita, S. Ishihara, A. Murakami, and H. Okada, Chemotherapy (Tokyo), 21, 1305 (1973).Google Scholar
  3. 3.
    J.J. Rasker, M.A.P.C. Poll, H. Beekhuis, M.G. Woldring, and H.O. Nieweg, J. Nucl. Med., 16, 1058 (1975).PubMedGoogle Scholar
  4. 4.
    E.A. Sausville, J. Peisach, and S.B. Horwitz, Biochem. Biophys. Res. Commun., 73, 814 (1976).PubMedCrossRefGoogle Scholar
  5. 5.
    T. Takita, Y. Muraoka, T. Nakatani, A. Fujii, Y. Iitaka, and H. Umezawa, J. Antibiot. (Tokyo), 31, 1073 (1978).Google Scholar
  6. 6.
    R. Ishida and T. Takahashi,Biochem. Biophys. Res. Commun., 166, 1432 (1975).CrossRefGoogle Scholar
  7. 7.
    A.D. Nunn, Int. J. Nucl. Med. Biol., 4, 216 (1977).CrossRefGoogle Scholar
  8. 8.
    B.M. Hoffman D.L. Diemente and F. Basolo J. Am. Chern. Soc. 92, 61 (1970).CrossRefGoogle Scholar
  9. 9.
    T. Yonetani, H. Yamamoto, and T. Iizuka, J. Biol. Chem.,249, 2169(1974).Google Scholar
  10. 10.
    M-Y.R. Wang, B.M. Hoffman, and P.F. Hollenberg, J. Biol. Chem., 252, 6268 (1977).PubMedGoogle Scholar
  11. 11.
    D. Diemente, B.M. Hoffman, and F. Basolo, J. Chem. Soc. Chem. Commun., 467 (1970).Google Scholar
  12. 12.
    E.W. Abel, J. Chem. Soc. Chem. Commun., 449 (1971).Google Scholar
  13. 13.
    T. Yonetani, H. Yamamoto, J.E. Erman, J.S. Leigh, and G.H. Reed, J. Biol. Chem., 247, 2447 (1972).PubMedGoogle Scholar
  14. 14.
    Y. Sugiura and K. Ishiza, J.Inorg. Biochem., in press.Google Scholar
  15. 15.
    Y. Sugiura, K. Ishiza, and K. Miyoshi, J. Antibiot. (Tokyo), 32, 453 (1979).Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1979

Authors and Affiliations

  • Yukio Sugiura

There are no affiliations available

Personalised recommendations